Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is a biopharmaceutical company specializing in developing therapies for mental health disorders, with a focus on its proprietary synthetic psilocybin formulation, COMP360. It recently reported positive results from two Phase 3 trials for COMP360 in treatment-resistant depression (TRD), and has a planned meeting with the FDA to discuss its new drug application (NDA) filing strategy. The company is also conducting trials for COMP360 in other indications, such as post-traumatic stress disorder (PTSD) and anorexia nervosa, and has secured significant funding and partnerships. With promising data and a solid pipeline, Compass Pathways is positioned for success in the rapidly growing field of psychedelic therapeutics.

Bears say

Compass Pathways is facing potential competition in the future and its clinical trials, while successful, have not shown strong enough results to convince the FDA to approve the treatment yet. Additionally, their drug's safety profile is clean, but lacks significant efficacy results, making it a less attractive option for patients and physicians. Finally, while the company has shown some diversity on the management and board levels, there is still room for improvement in terms of representation.

COMPASS Pathways (CMPS) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 8 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Apr 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.